BRAF and lung cancer: Another prospective, proof-of-concept study using the UltraSEEK oncogene panel found EBC effective at identifying clinically relevant lung cancer mutations (in genes EGFR, KRAS, PIK3CA, ERBB2, BRAF) and suggests its complementary role with plasma-based testing in liquid biopsy lung cancer diagnostics (72).